LFB USA
U.S. affiliate providing commercial access to an approved recombinant coagulation factor VIIa therapy for treatment of bleeding episodes in adolescents and adults with hemophilia A or B with inhibitors. Maintains a U.S. office in Framingham, MA and uses partnership/joint-venture arrangements to make the product available in the U.S. market.
Industries
Biotechnology
Biotechnology Research
Nr. of Employees
medium (51-250)
LFB USA
Patents
Products
Recombinant coagulation factor VIIa (approved hemostatic therapeutic)
An approved recombinant coagulation factor VIIa therapeutic indicated for treatment and control of bleeding episodes in adults and adolescents (12 years and older) with hemophilia A or B with inhibitors. Made available in the U.S. through commercial partnership arrangements.
Recombinant coagulation factor VIIa (approved hemostatic therapeutic)
An approved recombinant coagulation factor VIIa therapeutic indicated for treatment and control of bleeding episodes in adults and adolescents (12 years and older) with hemophilia A or B with inhibitors. Made available in the U.S. through commercial partnership arrangements.
Expertise Areas
- Commercialization and distribution of biologic therapeutics
- Hemostasis and coagulation therapeutics
- Partnership-based market access
- U.S. commercial operations for biologics
Key Technologies
- Recombinant protein therapeutics
- Biologic therapeutic commercialization